{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:46:09Z","timestamp":1765889169032,"version":"3.37.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with moderate-to-severe psoriasis are candidates for systemic treatment, but it is unknown how many receive such therapy at a national level in Denmark.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We aimed to determine the prevalence of conventional systemic therapy use in patients with moderate-to-severe psoriasis and, further, to investigate the time to discontinuation of conventional systemic therapy and initiation of biological therapy among biologic-na\u00efve patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This registry-based study identified a cohort of patients with psoriasis in Denmark. We estimated the prevalence of moderate-to-severe psoriasis at a national level using registry data. Inverse probability weighting was used to mitigate potential selection bias in the prevalence estimate of moderate-to-severe psoriasis. Analyses were then performed on the weighted cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of patients with psoriasis in Denmark, 10.9% were estimated to have moderate-to-severe psoriasis, of whom 62.3% received either conventional systemic or biological therapy, meaning 37.7% who were considered candidates for systemic therapy did not receive any systemic treatment. The study demonstrated that, comparing previous time periods with more recent years: (i) time on conventional systemic therapy for patients with moderate-to-severe psoriasis has become shorter, with a median (interquartile range) of 3.0\u2005years (0.6\u201310.0) in 1985\u20131994 vs. 0.6\u2005years (0.3\u20132.0) in 2014\u20132018; (ii) more patients initiated biologics as second-line therapy, with 69.5% in 2010\u20132013 vs. 71.2% in 2014\u20132018; and (iii) the median time from initiation of systemic therapy to initiation of biological therapy decreased from 13.3\u2005years (11.5\u201316.8) in 2010\u20132013 to 1.9\u2005years (1.7\u20132.4) in 2014\u20132018.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study found that nearly 37.7% of Danish patients with moderate-to-severe psoriasis do not receive systemic treatment even though they would qualify for this. Furthermore, for patients treated with conventional systemics, drug survival decreased during the observation period.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llad275","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T15:34:58Z","timestamp":1692718498000},"page":"35-41","source":"Crossref","is-referenced-by-count":3,"title":["Use of systemic and biological therapy in patients with moderate-to-severe psoriasis"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7419-7086","authenticated-orcid":false,"given":"Mie S","family":"Liljendahl","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Gentofte Hospitalsvej 15, 2900 Hellerup, University of Copenhagen , Denmark"},{"name":"Department of Dermatology and Venereology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Gentofte Hospitalsvej 15, 2900 Hellerup, University of Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tri-Long","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Section of Epidemiology, Department of Public Health, University of Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Gentofte Hospitalsvej 15, 2900 Hellerup, University of Copenhagen , Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-1816","authenticated-orcid":false,"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen , Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"2023122001324112400_llad275-B1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/11591580-000000000-00000","article-title":"The burden of moderate to severe psoriasis: an overview","volume":"30","author":"Raho","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"2023122001324112400_llad275-B2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2023122001324112400_llad275-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"2023122001324112400_llad275-B4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/09546634.2019.1597244","article-title":"Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study","volume":"31","author":"Puig","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"2023122001324112400_llad275-B5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10153431","article-title":"Are patients with psoriasis and psoriatic arthritis undertreated? A population-based study from Southern Italy","volume":"10","author":"Ingrasciotta","year":"2021","journal-title":"J Clin Med"},{"key":"2023122001324112400_llad275-B6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13555-016-0153-2","article-title":"Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data","volume":"7","author":"Armstrong","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023122001324112400_llad275-B7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2340\/00015555-2877","article-title":"Epidemiology and medication trends in patients with psoriasis: a nationwide population-based cohort study from Korea","volume":"98","author":"Han","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2023122001324112400_llad275-B8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2340\/00015555-2672","article-title":"Incidence and prevalence of psoriasis in Denmark","volume":"97","author":"Egeberg","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2023122001324112400_llad275-B9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2340\/00015555-3278","article-title":"Validation of psoriasis diagnoses in the Danish National Patient Register","volume":"99","author":"Loft","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2023122001324112400_llad275-B10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/jdv.15991","article-title":"Use of topical calcipotriol for identification of patients with psoriasis in administrative healthcare data \u2013 a validation study","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122001324112400_llad275-B11","first-page":"798","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2023122001324112400_llad275-B12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"7 Suppl.","key":"2023122001324112400_llad275-B13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J\u00a0Public Health"},{"key":"2023122001324112400_llad275-B14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41512-023-00141-5","article-title":"Development and internal validation of a diagnostic prediction model for psoriasis severity","volume":"7","author":"Liljendahl","year":"2023","journal-title":"Diagnostic Progn Res"},{"key":"2023122001324112400_llad275-B15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2007.06.042","article-title":"Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey","volume":"57","author":"Horn","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2023122001324112400_llad275-B16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023122001324112400_llad275-B17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s13555-020-00409-4","article-title":"Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature","volume":"10","author":"Balak","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023122001324112400_llad275-B18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2340\/00015555-2599","article-title":"Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a Danish expert meeting","volume":"97","author":"Raaby","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2023122001324112400_llad275-B19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000452740","article-title":"Efficacy and survival of systemic psoriasis treatments: an analysis of the Swiss Registry SDNTT","volume":"232","author":"Maul","year":"2016","journal-title":"Dermatology"},{"key":"2023122001324112400_llad275-B20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2340\/00015555-2130","article-title":"Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis","volume":"95","author":"Shalom","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2023122001324112400_llad275-B21","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/jdv.13682","article-title":"Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis","volume":"30","author":"D\u00e1vila-Seijo","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122001324112400_llad275-B22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40261-017-0508-1","article-title":"Initiation, switching, and cessation of psoriasis treatments among patients with moderate to severe psoriasis in the United States","volume":"37","author":"Armstrong","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2023122001324112400_llad275-B23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11845-016-1470-2","article-title":"Fumaric acid esters for psoriasis: a systematic review","volume":"186","author":"Smith","year":"2017","journal-title":"Ir J Med Sci"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad275\/52789553\/llad275.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/1\/35\/54647696\/llad275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/1\/35\/54647696\/llad275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T01:33:58Z","timestamp":1703036038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/1\/35\/7248972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,23]]},"published-print":{"date-parts":[[2023,12,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad275","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,8,23]]}}}